The number of people with susceptibility test result for rifampicin in Saint Kitts and Nevis
Saint Kitts and Nevis: The number of people with susceptibility test result for rifampicin was 0 in 2021. ◆ Volatile
Latest (2021)
0
Change on year
down 100.0%
World rank
146th
of 155 countries
All-time high
2
in 2019
All-time low
0
in 2018
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Saint Kitts and Nevis, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
Saint Kitts and Nevis recorded 0 for the number of people with susceptibility test result for rifampicin in 2021. That is the lowest value across all 5 years on record.
That represents a change of down 100.0% on the previous year and down 100.0% over five years.
That places Saint Kitts and Nevis 146th out of 155 countries with data for 2021, putting it in the bottom quarter.
The number of people with susceptibility test result for rifampicin in Saint Kitts and Nevis, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 1 | — |
| 2018 | 0 | -100.0% |
| 2019 | 2 | — |
| 2020 | 1 | -50.0% |
| 2021 | 0 | -100.0% |
Saint Kitts and Nevis compared with similar countries
- Saint Kitts and Nevis's 0 is below the median for high income countries, which is 142. (61 countries reporting)
- Saint Kitts and Nevis's 0 is below the median for Latin America & Caribbean, which is 406.5. (26 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 1 | 0 | 2 | 3 |
| 2020s | 0.5 | 0 | 1 | 2 |
Countries ranked near Saint Kitts and Nevis
- 143 Saint Lucia 2 compare
- 143 Bermuda 2 compare
- 143 Andorra 2 compare
- 146 Grenada 0 compare
- 146 Niue 0
- 146 Mauritania 0 compare
- 146 Barbados 0 compare
- 146 Sao Tome and Principe 0 compare
- 146 Vanuatu 0 compare
- 146 South Sudan 0 compare
- 146 Antigua and Barbuda 0
- 146 Saint Vincent and the Grenadines 0 compare
More health data for Saint Kitts and Nevis
- Un projection of annual infant deaths, annual growth rate -100 % change on previous year (2094)
- Heat deaths vs projected death rates, annual growth rate -0.2397 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,623 deaths per 1,000 people (2090)
- Number of infants who die before age 1 0 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2024)
- Population ages 00-04, female, annual growth rate -1.53 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0289 units per person (2025)
- Population ages 00-04, male, annual growth rate -1.34 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Saint Kitts and Nevis?
- The number of people with susceptibility test result for rifampicin in Saint Kitts and Nevis was 0 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Saint Kitts and Nevis?
- The highest recorded value was 2 in 2019.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Saint Kitts and Nevis?
- The lowest recorded value was 0 in 2018.
- How does Saint Kitts and Nevis rank for the number of people with susceptibility test result for rifampicin?
- Saint Kitts and Nevis ranks 146th out of 155 countries with data for 2021.
- Where does this Saint Kitts and Nevis data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).